Bevacizumab in the treatment of ovarian cancer

References

• JemalASiegelRXuJWardECancer Statistics, 2010CA Cancer J Clin20106027730020610543
   PubMed Web of Science ®Google Scholar
• BookmanMTrials with impact on clinical management: first lineInt J Gynecol Cancer200919Suppl 2S55S6219955916
   PubMed Web of Science ®Google Scholar
• OzolsRBundyBGreerBPhase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group studyJ Clin Oncol2003213194320012860964
   PubMed Web of Science ®Google Scholar
• MonkBChoiDPugmireGActivity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian cancerGynecol Oncol20059690290515721449
   PubMed Web of Science ®Google Scholar
• FolkmanJTumor angiogenesis: therapeutic implicationsN Engl J Med1971285118211864938153
   PubMed Web of Science ®Google Scholar
• BurgerRExperience with bevacizumab in the management of epithelial ovarian cancerJ Clin Oncol2007252902290817617521
   PubMed Web of Science ®Google Scholar
• RandallLMonkBBevacizumab toxicities and their management in ovarian cancerGynecol Oncol201011749750420363017
   PubMed Web of Science ®Google Scholar
• FerraraNHillanKGerberHDiscovery and development of bevacizumab, an anti-VEGF antibody for treating cancerNat Rev Drug Discov2004339140015136787
   PubMed Web of Science ®Google Scholar
• HurwitzHFehrenbacherLNovotnyWBevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancerN Engl J Med20043502335234215175435
   PubMed Web of Science ®Google Scholar
• SandlerAGrayRPerryMPaclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancerN Engl J Med20063552542255017167137
   PubMed Web of Science ®Google Scholar
• MillerKWangMGralowJPaclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancerN Engl J Med20073572666267618160686
   PubMed Web of Science ®Google Scholar
• EscudierBPluzanskaAKoralewskiPBevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trialLancet20073702103211118156031
   PubMed Web of Science ®Google Scholar
• McGuireWHoskinsWBradyMCyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancerN Engl J Med1996334167494563
   PubMed Web of Science ®Google Scholar
• MarkmanMBundyBAlbertsDPhase III trial of standard-dose intravenous cisplatin plus paclitaxel versus moderately high-dose carboplatin followed by intravenous paclitaxel and intraperitoneal cisplatin in small-volume stage III ovarian carcinoma: an intergroup study of the Gynecologic Oncology Group, Southwestern Oncology Group, and Eastern Cooperative Oncology GroupJ Clin Oncol2001191001100711181662
   PubMed Web of Science ®Google Scholar
• CannistraSEvaluating new regimens in recurrent ovarian cancer: how much evidence is good enough?J Clin Oncol2010283101310320516442
   PubMed Web of Science ®Google Scholar
• Pujade-LauraineEWagnerUAavall-LundqvistEPegylated liposomal doxorubicin and carboplatin compared with paclitaxel and carboplatin for patients with platinum-sensitive ovarian cancer in late relapseJ Clin Oncol201028332333920498395
   PubMed Web of Science ®Google Scholar
• CannistraSIs there a “best” choice of second-line agent in the treatment of recurrent, potentially platinum-sensitive ovarian cancer?J Clin Oncol2002201158116011870154
   PubMed Web of Science ®Google Scholar
• KumaranGJaysonGClampAAntiangiogenic drugs in ovarian cancerBr J Cancer20091001719002176
   PubMed Web of Science ®Google Scholar
• ByrneARossLHolashJVascular endothelial growth factor-trap decreases tumor burden, inhibits ascites, and causes dramatic vascular remodeling in an ovarian cancer modelClin Cancer Res2003957215728
   Google Scholar
• ShenGGhazizadehMKawanamiOPrognostic significance of vascular endothelial growth factor expression in human ovarian carcinomaBr J Cancer20008319620310901370
   PubMed Web of Science ®Google Scholar
• KambaTTamBHashizumeHVEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculatureAm J Physiol Heart Circ Physiol2006290H560H57616172168
   PubMed Web of Science ®Google Scholar
• FukumuraDJainRTumor microvasculature and microenvironment: targets for anti-angiogenesis and normalizationMicrovasc Res200774728417560615
   PubMed Web of Science ®Google Scholar
• BurgerRSillMMonkBPhase II trial of bevacizumab in persistent or recurrent epithelial ovarian cancer or primary peritoneal cancer: a Gynecologic Oncology Group StudyJ Clin Oncol2007255165517118024863
   PubMed Web of Science ®Google Scholar
• CannistraSMatulonisUPensonRPhase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancerJ Clin Oncol2007255180518618024865
   PubMed Web of Science ®Google Scholar
• GarciaAHirteHFlemingGPhase II clinical trial of bevacizumab and low-dose metronomic oral cyclophosphamide in recurrent ovarian cancer: a trial of the California, Chicago, and Princess Margaret Hospital phase II consortiaJ Clin Oncol200826768218165643
   PubMed Web of Science ®Google Scholar
• NimeiriHOzaAMorganREfficacy and safety of bevacizumab plus erlotinib for patients with recurrent ovarian, primary peritoneal, and fallopian tube cancer: a trial of the Chicago, PMH, and California Phase II ConsortiaGynecol Oncol2008110495518423560
   PubMed Web of Science ®Google Scholar
• AuranenAGrénmanSRadiation therapy and biological compounds for consolidation therapy in advanced ovarian cancerInt J Gynecol Cancer200818Suppl 1444618336400
   PubMed Web of Science ®Google Scholar
• ZhuXWuSDahutWRisks of proteinuria and hypertension with bevacizumab, an antibody against vascular endothelial growth factor: systematic review and meta-analysisAm J Kidney Dis20074918619317261421
   PubMed Web of Science ®Google Scholar
• IzzedineHRixeOBillemontBAngiogenesis inhibitor therapies: focus on kidney toxicity and hypertensionAm J Kidney Dis20075020321817660022
   PubMed Web of Science ®Google Scholar